Finance

Lists
Outlook: 20.0% bullish·10.0% bearish
Go to analysis
AKBA:NASDAQ
Akebia Therapeutics Inc
$0.54
+1.69%
(+0.0090) 1D
$0.55
+1.16% (+0.0063)
After hours
Closed: Nov 10, 4:00:00 PM GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for AKBA...
Open
$0.53
High
$0.55
Low
$0.49
Mkt. cap
151.23M
Avg. vol.
8.98M
Volume
5.49M
52-wk high
$1.89
52-wk low
$0.36
EPS
-$0.16
Beta
0.24
Shares outstanding
277.66M
No. of employees
194
Open
$0.53
High
$0.55
Low
$0.49
Mkt. cap
151.23M
Avg. vol.
8.98M
Volume
5.49M
52-wk high
$1.89
52-wk low
$0.36
EPS
-$0.16
Beta
0.24
Shares outstanding
277.66M
No. of employees
194
News stories
From web sources and news partners
About Akebia Therapeutics Inc
CEO-
Employees194
FoundedJan 1, 2007
HeadquartersCambridge, Massachusetts, United States
SectorHealth Care
IndustryBiotechnology
Websiteakebia.com
Analyst ratings
Based on 4 analysts giving stock ratings to AKBA in the past 3 months
Strong buy
Buy
4
Hold
0
Sell
0
12-month forecast
Based on 4 Wall Street analysts offering 12 month price targets for AKBA in the last 3 months.
Highest
Current $0.54
$4.50 (+730.56%)
Average
$3.88 (+616.13%)
Lowest
$3.00 (+453.71%)
Analyst
Recommendation
Action
Price target
Projected
Date
Matthew Caufield
H.C. Wainwright
Buy
Reiterated
$4.00
+638.3%
11/06/2026
Julian Harrison
BTIG
Buy
Maintained
$3.00
+453.7%
11/05/2026
Allison Bratzel
Piper Sandler
Buy
Maintained
$4.00
+638.3%
10/21/2026
Ed Arce
Westpark Capital
Buy
Initiated
$4.50
+730.6%
09/08/2026
Roanna Ruiz
Leerink Partners
Hold
Downgraded
$1.00
+84.6%
08/07/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Dec 2025
Mar 2026
Jun 2026
Sep 2026
Revenue
57.62M
53.54M
49.13M
36.90M
Cost of goods sold
10.93M
9.78M
9.58M
6.41M
Cost of revenue
10.93M
9.78M
9.58M
6.41M
Research and development expenses
26.65M
14.81M
14.06M
16.18M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
26.09M
30.44M
28.17M
23.53M
Operating expense
52.74M
45.24M
42.23M
39.71M
Total operating expenses
63.67M
55.02M
51.81M
46.12M
Operating income
-6.05M
-1.48M
-2.68M
-9.22M
Other non operating income
2.14M
459.00K
559.00K
425.00K
EBT including unusual items
-11.24M
-8.93M
-8.84M
-14.18M
EBT excluding unusual items
-8.73M
-5.71M
-5.19M
-11.94M
Income tax expense
1.01M
126.00K
70.00K
175.00K
Effective tax rate
-8.98%
-1.41%
-0.79%
-1.23%
Other operating expenses
-
-
-
-
Net income
-12.24M
-9.05M
-8.91M
-14.35M
Net profit margin
-21.25%
-16.91%
-18.13%
-38.90%
Earnings per share
-0.05
-0.03
-0.03
-0.05
Interest and investment income
-
-
-
-
Interest expense
-4.83M
-4.69M
-3.07M
-3.14M
Net interest expenses
-4.83M
-4.69M
-3.07M
-3.14M
Depreciation and amortization charges
-
-
-
-
EBITDA
-5.73M
-1.15M
-2.10M
-9.12M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps